JP2014514346A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014514346A5 JP2014514346A5 JP2014509378A JP2014509378A JP2014514346A5 JP 2014514346 A5 JP2014514346 A5 JP 2014514346A5 JP 2014509378 A JP2014509378 A JP 2014509378A JP 2014509378 A JP2014509378 A JP 2014509378A JP 2014514346 A5 JP2014514346 A5 JP 2014514346A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- antibody
- seq
- pharmaceutical
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 29
- 238000009472 formulation Methods 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 229960004914 vedolizumab Drugs 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 239000004475 Arginine Substances 0.000 claims 9
- 229930006000 Sucrose Natural products 0.000 claims 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 9
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 9
- 239000005720 sucrose Substances 0.000 claims 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 6
- 230000003796 beauty Effects 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000001802 infusion Methods 0.000 claims 4
- 238000001990 intravenous administration Methods 0.000 claims 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 4
- 229920000053 polysorbate 80 Polymers 0.000 claims 4
- 229940068968 polysorbate 80 Drugs 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000006172 buffering agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000012931 lyophilized formulation Substances 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161481533P | 2011-05-02 | 2011-05-02 | |
| US61/481,533 | 2011-05-02 | ||
| US201161550545P | 2011-10-24 | 2011-10-24 | |
| US61/550,545 | 2011-10-24 | ||
| US201261585859P | 2012-01-12 | 2012-01-12 | |
| US61/585,859 | 2012-01-12 | ||
| PCT/US2012/036072 WO2012151248A2 (en) | 2011-05-02 | 2012-05-02 | FORMULATION FOR ANTI-α4β7 ANTIBODY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017091845A Division JP6534415B2 (ja) | 2011-05-02 | 2017-05-02 | 抗α４β７抗体のための製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014514346A JP2014514346A (ja) | 2014-06-19 |
| JP2014514346A5 true JP2014514346A5 (enExample) | 2016-10-20 |
| JP6190360B2 JP6190360B2 (ja) | 2017-08-30 |
Family
ID=46085207
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014509378A Active JP6190360B2 (ja) | 2011-05-02 | 2012-05-02 | 抗α４β７抗体のための製剤 |
| JP2017091845A Active JP6534415B2 (ja) | 2011-05-02 | 2017-05-02 | 抗α４β７抗体のための製剤 |
| JP2018130978A Active JP6473845B2 (ja) | 2011-05-02 | 2018-07-10 | 抗α４β７抗体のための製剤 |
| JP2019074688A Active JP6878489B2 (ja) | 2011-05-02 | 2019-04-10 | 抗α４β７抗体のための製剤 |
| JP2021075479A Active JP7258941B2 (ja) | 2011-05-02 | 2021-04-28 | 抗α４β７抗体のための製剤 |
| JP2023061100A Active JP7492057B2 (ja) | 2011-05-02 | 2023-04-05 | 抗α４β７抗体のための製剤 |
| JP2024080117A Pending JP2024098027A (ja) | 2011-05-02 | 2024-05-16 | 抗α４β７抗体のための製剤 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017091845A Active JP6534415B2 (ja) | 2011-05-02 | 2017-05-02 | 抗α４β７抗体のための製剤 |
| JP2018130978A Active JP6473845B2 (ja) | 2011-05-02 | 2018-07-10 | 抗α４β７抗体のための製剤 |
| JP2019074688A Active JP6878489B2 (ja) | 2011-05-02 | 2019-04-10 | 抗α４β７抗体のための製剤 |
| JP2021075479A Active JP7258941B2 (ja) | 2011-05-02 | 2021-04-28 | 抗α４β７抗体のための製剤 |
| JP2023061100A Active JP7492057B2 (ja) | 2011-05-02 | 2023-04-05 | 抗α４β７抗体のための製剤 |
| JP2024080117A Pending JP2024098027A (ja) | 2011-05-02 | 2024-05-16 | 抗α４β７抗体のための製剤 |
Country Status (42)
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3431485B2 (en) | 2010-10-01 | 2024-09-04 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| KR101875155B1 (ko) | 2011-05-02 | 2018-07-09 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 항-α4β7 항체에 대한 제형 |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| HRP20190672T1 (hr) * | 2013-03-15 | 2019-08-23 | AbbVie Deutschland GmbH & Co. KG | Konjugirane formulacije anti-egfr protutijelo-lijek |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
| US11058768B2 (en) * | 2014-04-16 | 2021-07-13 | Biocon Ltd. | Stable protein formulations comprising a molar excess of sorbitol |
| EP4268820A3 (en) * | 2014-10-06 | 2024-01-17 | ChemoCentryx, Inc. | Combination therapy of c-c chemokine receptor-9 (ccr9) inhibitors and anti-alpha4beta7 integrin blocking antibodies for the treatment of inflammatory bowel disease |
| WO2016086147A1 (en) | 2014-11-26 | 2016-06-02 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| US20170360926A1 (en) | 2014-12-24 | 2017-12-21 | Millennium Pharmaceuticals, Inc. | PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY |
| MA41636A (fr) * | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
| SG11201800864XA (en) * | 2015-08-11 | 2018-03-28 | Univ Osaka | Antibody |
| WO2017087735A1 (en) * | 2015-11-18 | 2017-05-26 | Millennium Pharmaceuticals, Inc. | Method for treating crohn's disease |
| USD866757S1 (en) | 2016-03-11 | 2019-11-12 | Millennium Pharmaceuticals, Inc. | Autoinjector |
| CN117298268A (zh) | 2016-03-14 | 2023-12-29 | 千禧制药公司 | 治疗或预防移植物抗宿主疾病的方法 |
| AU2017234009B2 (en) * | 2016-03-14 | 2024-06-06 | Millennium Pharmaceuticals, Inc. | Method of preventing graft versus host disease |
| WO2017158393A1 (en) * | 2016-03-18 | 2017-09-21 | Oslo University Hospital Hf | Methods of treating graft-versus-host disease |
| TW201735949A (zh) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法 |
| JP7069032B2 (ja) | 2016-03-24 | 2022-05-17 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
| ES2962373T3 (es) * | 2016-04-13 | 2024-03-18 | Medimmune Llc | Uso de aminoácidos como compuestos estabilizadores en composiciones farmacéuticas que contienen altas concentraciones de agentes terapéuticos basados en proteínas |
| WO2017192867A1 (en) | 2016-05-04 | 2017-11-09 | Millennium Pharmaceuticals, Inc. | Triple combination therapy for treating inflammatory bowel disease |
| MA45245A (fr) * | 2016-06-12 | 2019-04-17 | Millennium Pharm Inc | Méthode de traitement de maladie intestinale inflammatoire |
| US11351256B2 (en) * | 2016-10-07 | 2022-06-07 | Regeneron Pharmaceuticals, Inc. | Room temperature stable lyophilized protein |
| WO2018104893A1 (en) | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life |
| DK3558391T3 (da) * | 2016-12-23 | 2022-05-09 | Immunogen Inc | Immunkonjugater med adam9 som mål og fremgangsmåder til anvendelse deraf |
| KR20190141148A (ko) * | 2017-04-28 | 2019-12-23 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 소아 장애를 치료하는 방법 |
| EP3624846B1 (en) | 2017-05-16 | 2024-08-07 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan |
| US20200087401A1 (en) * | 2017-05-26 | 2020-03-19 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of chronic pouchitis |
| EP3474820B1 (en) | 2017-08-24 | 2024-02-07 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
| EP3459527B1 (en) * | 2017-09-20 | 2022-11-23 | Tillotts Pharma Ag | Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization |
| KR20200069316A (ko) | 2017-10-12 | 2020-06-16 | 노보 노르디스크 에이/에스 | 의료 요법에서의 세마글루타이드 |
| US20210031012A1 (en) | 2018-01-26 | 2021-02-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
| AU2019251453A1 (en) * | 2018-04-10 | 2020-11-26 | Dr. Reddy’S Laboratories Limited | Stable formulations of therapeutic antibody |
| CN112218654A (zh) * | 2018-04-10 | 2021-01-12 | 雷迪博士实验室有限公司 | 抗体制剂 |
| SG11202009872YA (en) * | 2018-04-10 | 2020-11-27 | Dr Reddys Laboratories Ltd | Stable antibody formulation |
| CN112203688A (zh) | 2018-05-31 | 2021-01-08 | 小野药品工业株式会社 | 用于确定免疫检查点抑制剂的有效性的生物标志物 |
| WO2019246313A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| EP3810268A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| WO2019246455A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| US12171764B2 (en) | 2018-06-20 | 2024-12-24 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor |
| CN109239335A (zh) * | 2018-09-11 | 2019-01-18 | 广州万孚生物技术股份有限公司 | 联检试纸条及其制备方法 |
| WO2020123241A1 (en) * | 2018-12-10 | 2020-06-18 | Clear Creek Bio, Inc. | Multiphasic dosing regimens for treating cancer |
| MX2021009851A (es) | 2019-02-18 | 2021-09-10 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos. |
| EP3956358A4 (en) * | 2019-04-17 | 2023-01-25 | Millennium Pharmaceuticals, Inc. | COMBINATION THERAPY WITH ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR |
| CA3143246A1 (en) * | 2019-06-10 | 2020-12-17 | Takeda Pharmaceutical Company Limited | Cell culture methods and compositions for antibody production |
| AU2020290943A1 (en) * | 2019-06-10 | 2022-02-03 | Takeda Pharmaceutical Company Limited | Methods of producing an anti-α4β7 antibody |
| TW202112800A (zh) * | 2019-06-10 | 2021-04-01 | 美商千禧製藥公司 | 抗體純化方法及其組成物 |
| US10792360B1 (en) | 2019-11-21 | 2020-10-06 | Chemocentryx, Inc. | Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies |
| PE20230819A1 (es) | 2020-02-18 | 2023-05-19 | Novo Nordisk As | Composiciones y usos de glp-1 |
| CN113577281A (zh) * | 2020-04-30 | 2021-11-02 | 中国科学院分子细胞科学卓越创新中心 | 调控整合素β亚基的试剂和方法 |
| AR122983A1 (es) | 2020-07-16 | 2022-10-19 | Abbvie Inc | ANTICUERPOS ANTI-a4b7 |
| US20240100158A1 (en) * | 2021-01-20 | 2024-03-28 | Dr. Reddy’S Laboratories Limited | Freeze dried antibody formulations and methods thereof |
| AU2022271025A1 (en) * | 2021-05-07 | 2023-12-14 | Dr. Reddy’S Laboratories Limited | A method of improving stability of an antibody formulation |
| CN113813377A (zh) * | 2021-09-07 | 2021-12-21 | 杭州远大生物制药有限公司 | 抗α4β7抗体制剂及其应用 |
| AU2024282654A1 (en) | 2023-05-30 | 2025-12-04 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| WO2024252368A2 (en) | 2023-06-09 | 2024-12-12 | Takeda Pharmaceutical Company Limited | Methods and compositions for treating ulcerative colitis |
| WO2025133872A1 (en) * | 2023-12-19 | 2025-06-26 | Intas Pharmaceuticals Ltd. | Method for reducing oxidation levels in vedolizumab during cell culture process |
| WO2025149974A1 (en) | 2024-01-11 | 2025-07-17 | Takeda Pharmaceutical Company Limited | Combination therapy with an anti-alpha4beta7 antibody |
| WO2025177214A1 (en) | 2024-02-20 | 2025-08-28 | Takeda Pharmaceutical Company Limited | Therapeutic methods |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US774216A (en) | 1903-11-19 | 1904-11-08 | Alexander F Ward | Machine for pointing and lapping hoops. |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5403919A (en) | 1987-08-11 | 1995-04-04 | Board Of Trustees Of The Leland Stanford Junior University Stanford University | Method to control leukocyte extravasation |
| ATE114478T1 (de) | 1987-08-11 | 1994-12-15 | Univ Leland Stanford Junior | Verfahren zur kontrolle der leukozyten- extravasation. |
| US5538724A (en) | 1987-08-11 | 1996-07-23 | The Board Of Trustees For The Leland Stanford Junior Univ. | Method of control leukocyte extravasation |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| US5223392A (en) | 1988-01-25 | 1993-06-29 | Exocell, Inc. | Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore |
| WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
| WO1990007321A2 (en) | 1988-12-23 | 1990-07-12 | The Board Of Trustees Of The Leland Stanford Junior University | Lymphocyte receptor homing sequences and their uses |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5730978A (en) | 1989-09-01 | 1998-03-24 | Fred Hutchinson Cancer Research Center | Inhibition of lymphocyte adherence with α4β1-specific antibodies |
| IL113261A (en) | 1989-09-01 | 1996-10-16 | Hutchinson Fred Cancer Res | Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DK0531472T3 (da) | 1991-03-06 | 2003-12-01 | Merck Patent Gmbh | Humaniserede monoklonale antistoffer |
| US5665595A (en) | 1991-06-07 | 1997-09-09 | Dowelanco | Immunoglobulins against insect tissue |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5871734A (en) | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
| EP0625912B1 (en) | 1992-02-12 | 1997-04-16 | Biogen, Inc. | Treatment for inflammatory bowel disease |
| US5932214A (en) * | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
| AU4390893A (en) | 1992-05-21 | 1993-12-13 | Center For Blood Research, Inc., The | A novel receptor for alpha4 integrins and methods based thereon |
| AU5732694A (en) | 1992-12-01 | 1994-06-22 | Protein Design Labs, Inc. | Humanized antibodies reactive with cd18 |
| WO1994013312A1 (en) | 1992-12-15 | 1994-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Mucosal vascular addressin, dna and expression |
| DK0678122T3 (da) | 1993-01-12 | 2000-03-06 | Biogen Inc | Rekombinante anti-VLA4 antistofmolekyler |
| WO1994017828A2 (en) | 1993-02-09 | 1994-08-18 | Biogen, Inc. | Treatment for insulin dependent diabetes |
| US6017695A (en) | 1993-03-26 | 2000-01-25 | Becton Dickinson And Company | Nucleic acids encoding human cell adhesion molecule |
| JPH06303990A (ja) | 1993-04-24 | 1994-11-01 | Kanebo Ltd | モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法 |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| JP4115517B2 (ja) | 1994-01-25 | 2008-07-09 | エラン ファーマシューティカルズ， インコーポレイテッド | 白血球付着分子 ｖｌａ−４に対するヒト化抗体 |
| US5594120A (en) | 1994-02-18 | 1997-01-14 | Brigham And Women's Hospital, Inc. | Integrin alpha subunit |
| US5610281A (en) | 1994-05-03 | 1997-03-11 | Brigham & Women's Hospital, Inc. | Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes |
| GB2292079B (en) | 1994-08-12 | 1998-07-15 | Flexpharm Ltd | Coated prednisolone preparation for the treatment of inflamatory bowel disease |
| US5624321A (en) | 1994-12-23 | 1997-04-29 | Snyder; Stephen D. | Spring-actuated swing device |
| US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
| US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| PT808367E (pt) | 1995-02-10 | 2007-10-22 | Millennium Pharm Inc | Adressinas vasculares da mucosa e suas utilizações |
| US7750137B2 (en) | 1995-09-01 | 2010-07-06 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6037324A (en) | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
| US6015662A (en) | 1996-01-23 | 2000-01-18 | Abbott Laboratories | Reagents for use as calibrators and controls |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| EP0852951A1 (de) * | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US20010046496A1 (en) * | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| ATE454137T1 (de) | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| US7053202B2 (en) | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
| DE10163459A1 (de) | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor |
| PL215263B1 (pl) | 2002-02-25 | 2013-11-29 | Elan Pharm Inc | Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku |
| NZ566263A (en) | 2002-05-24 | 2009-09-25 | Millennium Pharm Inc | CCR9 inhibitors and methods of use thereof |
| ATE363470T1 (de) | 2002-11-18 | 2007-06-15 | Chemocentryx Inc | Arylsulfonamide |
| AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| DK1610820T4 (da) | 2003-04-04 | 2013-11-04 | Genentech Inc | Høj-koncentration antistof- og proteinformuleringer |
| MY162179A (en) * | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
| SI1784426T1 (sl) * | 2004-09-03 | 2012-03-30 | Genentech Inc | Humanizirani antagonisti proti beta in njihove uporabe |
| AU2006316629A1 (en) | 2005-11-17 | 2007-05-31 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with alpha 4 beta 7 integrin |
| WO2007074880A1 (ja) | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
| AU2007212147A1 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| GEP20125628B (en) | 2006-04-21 | 2012-09-10 | Novartis Ag | Pharmaceutical compositions containing antagonist anti-cd40 antibody |
| PE20081179A1 (es) | 2006-10-06 | 2008-09-29 | Amgen Inc | Formulaciones estables de anticuerpos egfr |
| CA2666492C (en) | 2006-10-20 | 2012-07-17 | Douglas Rehder | Stable polypeptide formulations |
| WO2008140602A2 (en) | 2006-12-07 | 2008-11-20 | The Govenment Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services | USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND α4β7 INTEGRIN |
| CN101553504A (zh) | 2006-12-11 | 2009-10-07 | 豪夫迈·罗氏有限公司 | Aβ抗体胃肠外制剂 |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| SG183709A1 (en) * | 2007-08-08 | 2012-09-27 | Abbott Lab | Compositions and methods for crystallizing antibodies |
| WO2010100200A2 (en) * | 2009-03-05 | 2010-09-10 | Novartis Ag | Lyophilised antibody formulation |
| KR101391472B1 (ko) | 2009-03-20 | 2014-05-07 | 암젠 인크 | 알파-4-베타-7 이종이량체 특이적 길항제 항체 |
| WO2010148337A1 (en) * | 2009-06-18 | 2010-12-23 | Wyeth Llc | Lyophilized formulations for small modular immunopharmaceuticals |
| WO2011017070A1 (en) | 2009-07-28 | 2011-02-10 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| CN109734807A (zh) | 2011-03-31 | 2019-05-10 | 豪夫迈·罗氏有限公司 | 施用β7整联蛋白拮抗剂的方法 |
| KR101875155B1 (ko) | 2011-05-02 | 2018-07-09 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 항-α4β7 항체에 대한 제형 |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| WO2016086147A1 (en) * | 2014-11-26 | 2016-06-02 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| US20170360926A1 (en) | 2014-12-24 | 2017-12-21 | Millennium Pharmaceuticals, Inc. | PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY |
| WO2017192867A1 (en) | 2016-05-04 | 2017-11-09 | Millennium Pharmaceuticals, Inc. | Triple combination therapy for treating inflammatory bowel disease |
| MA45245A (fr) * | 2016-06-12 | 2019-04-17 | Millennium Pharm Inc | Méthode de traitement de maladie intestinale inflammatoire |
-
2012
- 2012-02-05 UA UAA201313899A patent/UA116189C2/uk unknown
- 2012-05-02 PL PL12721093T patent/PL2704798T3/pl unknown
- 2012-05-02 PH PH1/2013/502236A patent/PH12013502236A1/en unknown
- 2012-05-02 SI SI201231073T patent/SI2704798T1/sl unknown
- 2012-05-02 KR KR1020137031382A patent/KR20140145953A/ko not_active Ceased
- 2012-05-02 CA CA2834867A patent/CA2834867C/en active Active
- 2012-05-02 SG SG2013079686A patent/SG194652A1/en unknown
- 2012-05-02 EP EP24167556.0A patent/EP4378484A3/en active Pending
- 2012-05-02 EP EP12721093.8A patent/EP2704798B1/en active Active
- 2012-05-02 MY MYPI2016001847A patent/MY183471A/en unknown
- 2012-05-02 PL PL18150968.8T patent/PL3329965T3/pl unknown
- 2012-05-02 PE PE2018001579A patent/PE20190405A1/es unknown
- 2012-05-02 AU AU2012250873A patent/AU2012250873B2/en active Active
- 2012-05-02 TW TW101115712A patent/TWI556828B/zh active
- 2012-05-02 AR ARP120101539A patent/AR086237A1/es not_active Application Discontinuation
- 2012-05-02 CN CN201711161579.XA patent/CN108079291B/zh active Active
- 2012-05-02 IL IL296838A patent/IL296838A/en unknown
- 2012-05-02 KR KR1020177027571A patent/KR101923371B1/ko active Active
- 2012-05-02 MX MX2013012724A patent/MX348814B/es active IP Right Grant
- 2012-05-02 MX MX2018003210A patent/MX383317B/es unknown
- 2012-05-02 KR KR1020227038842A patent/KR20220154834A/ko not_active Ceased
- 2012-05-02 HU HUE18150968A patent/HUE071510T2/hu unknown
- 2012-05-02 PT PT181509688T patent/PT3329965T/pt unknown
- 2012-05-02 EP EP18150968.8A patent/EP3329965B1/en active Active
- 2012-05-02 ME MEP-2017-228A patent/ME02859B/me unknown
- 2012-05-02 EP EP17180246.5A patent/EP3263178A1/en active Pending
- 2012-05-02 ES ES12721093.8T patent/ES2645187T3/es active Active
- 2012-05-02 IL IL275038A patent/IL275038B2/en unknown
- 2012-05-02 JP JP2014509378A patent/JP6190360B2/ja active Active
- 2012-05-02 HU HUE12721093A patent/HUE036663T2/hu unknown
- 2012-05-02 IL IL296847A patent/IL296847A/en unknown
- 2012-05-02 CA CA3028209A patent/CA3028209C/en active Active
- 2012-05-02 DK DK12721093.8T patent/DK2704798T3/en active
- 2012-05-02 DK DK18150968.8T patent/DK3329965T3/da active
- 2012-05-02 KR KR1020187012689A patent/KR101923378B1/ko active Active
- 2012-05-02 KR KR1020207008950A patent/KR102275603B1/ko active Active
- 2012-05-02 EA EA201391614A patent/EA032729B1/ru not_active IP Right Cessation
- 2012-05-02 RS RS20171014A patent/RS56397B1/sr unknown
- 2012-05-02 UY UY0001034053A patent/UY34053A/es not_active Application Discontinuation
- 2012-05-02 HR HRP20171432TT patent/HRP20171432T1/hr unknown
- 2012-05-02 TW TW105130046A patent/TWI664978B/zh active
- 2012-05-02 GE GEAP201213304A patent/GEP201706734B/en unknown
- 2012-05-02 PE PE2013002431A patent/PE20141175A1/es active IP Right Grant
- 2012-05-02 KR KR1020217020871A patent/KR102465394B1/ko active Active
- 2012-05-02 FI FIEP18150968.8T patent/FI3329965T3/fi active
- 2012-05-02 CN CN201711309462.1A patent/CN108187042A/zh active Pending
- 2012-05-02 PT PT127210938T patent/PT2704798T/pt unknown
- 2012-05-02 BR BR112013028424-2A patent/BR112013028424A2/pt not_active Application Discontinuation
- 2012-05-02 MY MYPI2013003922A patent/MY172735A/en unknown
- 2012-05-02 ES ES18150968T patent/ES3016382T3/es active Active
- 2012-05-02 RS RS20250372A patent/RS66809B1/sr unknown
- 2012-05-02 SI SI201232089T patent/SI3329965T1/sl unknown
- 2012-05-02 SM SM20170508T patent/SMT201700508T1/it unknown
- 2012-05-02 MX MX2016012776A patent/MX356827B/es unknown
- 2012-05-02 CN CN201280030450.4A patent/CN103608071B/zh active Active
- 2012-05-02 LT LTEP12721093.8T patent/LT2704798T/lt unknown
- 2012-05-02 LT LTEP18150968.8T patent/LT3329965T/lt unknown
- 2012-05-02 WO PCT/US2012/036072 patent/WO2012151248A2/en not_active Ceased
- 2012-05-02 TW TW107138209A patent/TWI664980B/zh active
- 2012-05-02 US US14/114,832 patent/US9764033B2/en active Active
- 2012-05-02 CN CN201711310404.0A patent/CN108129565B/zh active Active
- 2012-05-02 SM SM20250218T patent/SMT202500218T1/it unknown
- 2012-05-02 KR KR1020187033652A patent/KR102096484B1/ko active Active
- 2012-05-02 HR HRP20250472TT patent/HRP20250472T1/hr unknown
- 2012-05-02 PH PH1/2018/500030A patent/PH12018500030B1/en unknown
- 2012-05-02 KR KR1020257019984A patent/KR20250094743A/ko active Pending
- 2012-05-02 US US13/462,414 patent/US20120282249A1/en not_active Abandoned
- 2012-05-02 UA UAA201707804A patent/UA126545C2/uk unknown
-
2013
- 2013-10-28 IL IL229104A patent/IL229104A0/en unknown
- 2013-10-29 ZA ZA2013/08069A patent/ZA201308069B/en unknown
- 2013-10-30 DO DO2013000253A patent/DOP2013000253A/es unknown
- 2013-10-30 CL CL2013003146A patent/CL2013003146A1/es unknown
- 2013-10-31 MX MX2021006723A patent/MX2021006723A/es unknown
- 2013-11-01 CO CO13259825A patent/CO6801647A2/es not_active Application Discontinuation
- 2013-11-26 EC ECSP13013050 patent/ECSP13013050A/es unknown
- 2013-11-26 MA MA36501A patent/MA35136B1/fr unknown
- 2013-12-19 CR CR20130677A patent/CR20130677A/es unknown
-
2016
- 2016-07-20 US US15/215,000 patent/US10004808B2/en active Active
- 2016-07-20 US US15/214,993 patent/US10143752B2/en active Active
- 2016-07-20 US US15/215,012 patent/US9663579B2/en active Active
- 2016-09-19 AU AU2016231469A patent/AU2016231469B2/en active Active
-
2017
- 2017-04-05 CL CL2017000830A patent/CL2017000830A1/es unknown
- 2017-05-02 JP JP2017091845A patent/JP6534415B2/ja active Active
- 2017-08-16 US US15/678,744 patent/US20190076532A1/en not_active Abandoned
- 2017-10-11 CY CY20171101056T patent/CY1119435T1/el unknown
- 2017-10-20 ZA ZA2017/07158A patent/ZA201707158B/en unknown
-
2018
- 2018-03-20 US US15/927,032 patent/US20180207279A1/en not_active Abandoned
- 2018-06-21 HK HK18107977.2A patent/HK1249466A1/en unknown
- 2018-06-21 US US16/015,167 patent/US20180289811A1/en not_active Abandoned
- 2018-07-10 JP JP2018130978A patent/JP6473845B2/ja active Active
- 2018-10-18 ZA ZA2018/06946A patent/ZA201806946B/en unknown
- 2018-12-03 US US16/208,294 patent/US20190231878A1/en active Pending
- 2018-12-11 AU AU2018278866A patent/AU2018278866B2/en active Active
-
2019
- 2019-03-20 AU AU2019201926A patent/AU2019201926A1/en not_active Abandoned
- 2019-04-10 JP JP2019074688A patent/JP6878489B2/ja active Active
- 2019-06-26 IL IL267668A patent/IL267668B/en active IP Right Grant
- 2019-12-23 US US16/726,092 patent/US12171832B2/en active Active
-
2020
- 2020-01-15 US US16/743,813 patent/US12053526B2/en active Active
- 2020-02-13 PH PH12020500336A patent/PH12020500336A1/en unknown
- 2020-10-08 AU AU2020250249A patent/AU2020250249B2/en active Active
-
2021
- 2021-04-28 JP JP2021075479A patent/JP7258941B2/ja active Active
-
2022
- 2022-02-22 US US17/652,090 patent/US20220370617A1/en active Pending
- 2022-04-29 EC ECSENADI202234515A patent/ECSP22034515A/es unknown
- 2022-09-15 AU AU2022231726A patent/AU2022231726B2/en active Active
-
2023
- 2023-04-05 JP JP2023061100A patent/JP7492057B2/ja active Active
-
2024
- 2024-05-16 JP JP2024080117A patent/JP2024098027A/ja active Pending
- 2024-07-19 US US18/778,906 patent/US20250000981A1/en active Pending
- 2024-10-21 US US18/922,371 patent/US20250041424A1/en active Pending
-
2025
- 2025-04-04 AU AU2025202434A patent/AU2025202434A1/en active Pending
- 2025-05-29 US US19/222,996 patent/US20250288679A1/en active Pending
- 2025-06-05 US US19/230,064 patent/US20250295786A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014514346A5 (enExample) | ||
| JP2014515763A5 (enExample) | ||
| JP2017160208A5 (enExample) | ||
| KR102359181B1 (ko) | 항-ｒｓｖ 모노클로날 항체 제제 | |
| JP2021504372A5 (enExample) | ||
| IL274846B1 (en) | FORMULATION FOR ANTI-a4b7 ANTIBODY | |
| JP2016515511A5 (enExample) | ||
| JP2017537105A5 (enExample) | ||
| JP2021501214A5 (enExample) | ||
| JP2016528247A5 (enExample) | ||
| JP2015231997A5 (enExample) | ||
| JP2016529255A5 (enExample) | ||
| TW202005981A (zh) | 高親和性、異構體選擇性之TGFβ1抑制劑及其用途 | |
| JP2020516240A5 (enExample) | ||
| JP2006522830A5 (enExample) | ||
| JP2018507202A (ja) | モノクローナル抗体のための安定的な液体製剤 | |
| JP2013543505A5 (enExample) | ||
| JP2019514998A5 (enExample) | ||
| JP2016534052A5 (enExample) | ||
| JP2014522843A5 (enExample) | ||
| JP2014530244A5 (enExample) | ||
| JP2015525798A5 (enExample) | ||
| BR112021010789A2 (pt) | Anticorpos anti-il-36r para o tratamento de pustulose palmoplantar | |
| JP2016508973A5 (enExample) | ||
| JP2019509311A5 (enExample) |